Hepatosplenic T cell lymphoma: Difference between revisions
No edit summary |
|||
| Line 17: | Line 17: | ||
==Pathophysiology== | ==Pathophysiology== | ||
* Hepatosplenic T-cell lymphoma is a peripheral T-cell lymphoma, a type of non Hodgkin's lymphoma. | * Hepatosplenic T-cell lymphoma is a peripheral T-cell lymphoma, a type of non Hodgkin's lymphoma<ref name="pmid28516671">{{cite journal| author=Armitage JO| title=The aggressive peripheral T-cell lymphomas: 2017. | journal=Am J Hematol | year= 2017 | volume= 92 | issue= 7 | pages= 706-715 | pmid=28516671 | doi=10.1002/ajh.24791 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28516671 }} </ref>. | ||
* It is also known as ‘gamma-delta hepatosplenic T-cell lymphoma. | * It is also known as ‘gamma-delta hepatosplenic T-cell lymphoma<ref name="pmid30656034">{{cite journal| author=Brandt PH, Rahmat LT, Ali SS| title=A rare case of hepatosplenic gamma-delta T-cell lymphoma and secondary hemophagocytic lymphohistiocytosis. | journal=Clin Case Rep | year= 2019 | volume= 7 | issue= 1 | pages= 164-169 | pmid=30656034 | doi=10.1002/ccr3.1924 | pmc=6333078 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30656034 }} </ref>. | ||
* It usually occurs in young men with history of immunosuppression including solid organ transplantation and leukemia. | * It usually occurs in young men with history of immunosuppression including solid organ transplantation and leukemia<ref name="pmid29933321">{{cite journal| author=Choi Y, Jeon SY, Yoo WH| title=Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor-α Inhibitors for Ankylosing Spondylitis. | journal=J Clin Rheumatol | year= 2018 | volume= | issue= | pages= | pmid=29933321 | doi=10.1097/RHU.0000000000000805 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29933321 }} </ref>. | ||
* Patients with inflammatory bowel diseases receiving immunosuppressants and anti-tumor necrosis factor-α agent are also at risk for developing hepatosplenic T-cell lymphoma. | * Patients with inflammatory bowel diseases receiving immunosuppressants and anti-tumor necrosis factor-α agent are also at risk for developing hepatosplenic T-cell lymphoma. | ||
* The T-cell receptor consists of either a gamma delta or aplha beta entity on their cell surface which are a part of the innate immune system. | * The T-cell receptor consists of either a gamma delta or aplha beta entity on their cell surface which are a part of the innate immune system<ref name="pmid30596219">{{cite journal| author=Gowda L, Foss F| title=Hepatosplenic T-Cell Lymphomas. | journal=Cancer Treat Res | year= 2019 | volume= 176 | issue= | pages= 185-193 | pmid=30596219 | doi=10.1007/978-3-319-99716-2_9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30596219 }} </ref><ref name="pmid1698028">{{cite journal| author=Gaulard P, Bourquelot P, Kanavaros P, Haioun C, Le Couedic JP, Divine M et al.| title=Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. | journal=Am J Pathol | year= 1990 | volume= 137 | issue= 3 | pages= 617-28 | pmid=1698028 | doi= | pmc=1877506 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1698028 }} </ref>. | ||
* Gamma delta T cells represent the first line of defense against bacterial peptides, such as heat-shock proteins. | * Gamma delta T cells represent the first line of defense against bacterial peptides, such as heat-shock proteins. | ||
* Gamma delta T cells are CD4 and CD8 negative, but CD56 positive which is NK cell marker. | * Gamma delta T cells are CD4 and CD8 negative, but CD56 positive which is NK cell marker. | ||
| Line 43: | Line 43: | ||
==Causes== | ==Causes== | ||
Common causes of hepatosplenic t cell lymphoma are: | Common causes of hepatosplenic t cell lymphoma are<ref name="pmid29337025">{{cite journal| author=Yabe M, Miranda RN, Medeiros LJ| title=Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. | journal=Hum Pathol | year= 2018 | volume= 74 | issue= | pages= 5-16 | pmid=29337025 | doi=10.1016/j.humpath.2018.01.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29337025 }} </ref>: | ||
* Inflammatory bowel disease | * Inflammatory bowel disease | ||
* Organ transplant patients (reciever) | * Organ transplant patients (reciever) | ||
| Line 74: | Line 74: | ||
=== Natural history === | === Natural history === | ||
* Patients have a history of immunosupression such as inflammatory bowel disease under treatment or organ transplant. | * Patients have a history of immunosupression such as inflammatory bowel disease under treatment or organ transplant<ref name="pmid19237479">{{cite journal| author=Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE et al.| title=Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. | journal=Ann Oncol | year= 2009 | volume= 20 | issue= 6 | pages= 1080-5 | pmid=19237479 | doi=10.1093/annonc/mdn751 | pmc=4092251 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19237479 }} </ref>. | ||
* The mean age group is 35 years and most of the patients are males. | * The mean age group is 35 years and most of the patients are males. | ||
* Initial symptoms are fever, weight loss, night sweats and then progress to more severe symptoms depending on the organ involvement but there is no lymphadenopathy. | * Initial symptoms are fever, weight loss, night sweats and then progress to more severe symptoms depending on the organ involvement but there is no lymphadenopathy. | ||
| Line 97: | Line 97: | ||
=== Prognosis === | === Prognosis === | ||
* The prognosis is very poor, with patients dying within 2-3 years of diagnosis even after recieving treatment. | * The prognosis is very poor, with patients dying within 2-3 years of diagnosis even after recieving treatment<ref name="pmid26872013">{{cite journal| author=Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y et al.| title=Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. | journal=Am J Surg Pathol | year= 2016 | volume= 40 | issue= 5 | pages= 676-88 | pmid=26872013 | doi=10.1097/PAS.0000000000000614 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26872013 }} </ref>. | ||
==Diagnosis== | ==Diagnosis== | ||
Revision as of 23:14, 21 January 2019
For patient information, click here
|
Hepatosplenic T cell lymphoma Microchapters |
|
Differentiating Hepatosplenic T cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatosplenic T cell lymphoma On the Web |
|
American Roentgen Ray Society Images of Hepatosplenic T cell lymphoma |
|
Directions to Hospitals Treating Hepatosplenic T cell lymphoma |
|
Risk calculators and risk factors for Hepatosplenic T cell lymphoma |
- Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Synonyms and Keywords: Hepatosplenic γδ T-cell lymphoma, Hepatosplenic gamma delta T-cell lymphoma, HSTCL
Synonyms and keywords:
Overview
Historical Perspective
Hepatosplenic T cell lymphoma was discovered by Farcet et al in 1990.
Classification
There is no established system for the classification of hepatosplenic t cell lymphoma.
Pathophysiology
- Hepatosplenic T-cell lymphoma is a peripheral T-cell lymphoma, a type of non Hodgkin's lymphoma[1].
- It is also known as ‘gamma-delta hepatosplenic T-cell lymphoma[2].
- It usually occurs in young men with history of immunosuppression including solid organ transplantation and leukemia[3].
- Patients with inflammatory bowel diseases receiving immunosuppressants and anti-tumor necrosis factor-α agent are also at risk for developing hepatosplenic T-cell lymphoma.
- The T-cell receptor consists of either a gamma delta or aplha beta entity on their cell surface which are a part of the innate immune system[4][5].
- Gamma delta T cells represent the first line of defense against bacterial peptides, such as heat-shock proteins.
- Gamma delta T cells are CD4 and CD8 negative, but CD56 positive which is NK cell marker.
- Gamma delta cells respond to a stimuli and are responsible for lymphokine production and proliferation.
- Gamma delta cells are predominantly located in the spleen, liver sinusoids and intestinal epithelium.
- 75 % of the cases are of gamma delta phenotype and the rest are apha beta phenotype.
- Chronic antigen stimulation in states of immunosuppression is responsible for the deveopment of the lymphoma.
- Isochromosome of the long arm of chromosome 7 is a genetic abnormality described in hepatosplenic t cell lymphoma. It could also be in association with trisomy 8 and a loss of a sex chromosome.
- Mutations in SETD2, INO80, TET3 and STAT5B occur exclusively in hepatosplenic t cell lymphoma as compared to other T and B cell lymphoma types.
- The lymphoma is characterized by malignant T-cell proliferation in the sinusoids of the liver, sinuses and red pulp of the spleen, and sinuses of the bone marrow.
- Splenic involvement is characterized by diffuse involvement of the red pulp with small-to-medium-sized atypical lymphocytes.
- The atypical lymphocytes are present within the cords and sinuses of the red pulp.
- There occurs a complete loss of the white pulp.
- The liver also shows sinusoidal infiltration by neoplastic lymphoid cells.
- The bone marrow is characterized by neoplastic cells in the sinusoids.
- Bone marrow infiltration results in pancytopenia.
- The lymphoma cells are typically CD2+, CD3+, CD4−, CD5−, CD7+, CD8− CD42+, CD52+, CD76+, CD82+ with either gamma-delta or alpha-beta T-cell phenotypic receptor expression.
- It manifests as hepatosplenomegaly without peripheral lymphadenopathy.
- Pancytopenia and abnormal liver functions are the laboratory findings.
- Histology and immunohistochemistry of the tumor biopsy shows portal and sinusoidal infiltration by atypical small-to-medium sized lymphocytes with hyperchromatic nuclei and low mitotic activity.
Causes
Common causes of hepatosplenic t cell lymphoma are[6]:
- Inflammatory bowel disease
- Organ transplant patients (reciever)
- Immunosuppresent medications
- Thiopurines
- Infliximab
- Cyclophosphamide
- Vincristine
- Doxorubicin
Differentiating hepatosplenic t cell lymphoma from Other Diseases
Epidemiology and Demographics
- The incidence of hepatosplenic t cell lymphoma is 0.3 per 100000 individuals per year.
- It occurs in younger group of patients, most cases falling in 20-40 years of age group.
- Men are more affected than the females.
Risk Factors
Common risk factors include:
- Immunodeficiency diseases.
- Patients on immunosuppresant medications.
- Patients on chemotherapy.
- Inflammatory bowel disease
- Organ transplant patients.
Screening
There is insufficient evidence to recommend routine screening for hepatosplenic t cell lymphoma.
Natural History, Complications, and Prognosis
Natural history
- Patients have a history of immunosupression such as inflammatory bowel disease under treatment or organ transplant[7].
- The mean age group is 35 years and most of the patients are males.
- Initial symptoms are fever, weight loss, night sweats and then progress to more severe symptoms depending on the organ involvement but there is no lymphadenopathy.
- Patients also present with symptoms of liver, spleen and bone marrow dysfunction.
- If left untreated, patients can develop liver failure, pancytopenia or spleen rupture.
Complications
- Hepatomegaly
- Hepatic failure
- Portal vein thrombosis
- Splenomegaly
- Splenic infarction
- Spleen rupture
- Splenic vein thrombosis
- Anemia
- Thrombocytopenia
- Neutropenia
- Neurological dysfunction if metastasizes to brain.
- Intestinal perforation
- Intestinal obstruction
Prognosis
- The prognosis is very poor, with patients dying within 2-3 years of diagnosis even after recieving treatment[8].
Diagnosis
Diagnostic Study of Choice
- Biopsy of the tumor is the gold standard diagnostic test for diagnosing hepatosplenic t cell lymphoma.
- CT scan and PET scan are used to assess the spread of the lymphoma.
Symptoms
- Fever
- Weight loss
- Night sweats
- Pain abdomen
- Jaundice
- Fatigue
- Recurrent infections
- Bleeding
Physical Examination
Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].
OR
Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
The presence of [finding(s)] on physical examination is diagnostic of [disease name].
OR
The presence of [finding(s)] on physical examination is highly suggestive of [disease name].
Laboratory Findings
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal among patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Electrocardiogram
There are no ECG findings associated with [disease name].
OR
An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
X-ray
There are no x-ray findings associated with [disease name].
OR
An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with [disease name].
OR
Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
CT scan
There are no CT scan findings associated with [disease name].
OR
[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
MRI
There are no MRI findings associated with [disease name].
OR
[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Other Imaging Findings
There are no other imaging findings associated with [disease name].
OR
[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
There are no other diagnostic studies associated with [disease name].
OR
[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Surgery
Surgical intervention is not recommended for the management of [disease name].
OR
Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
Surgery is the mainstay of treatment for [disease or malignancy].
Primary Prevention
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
References
- ↑ Armitage JO (2017). "The aggressive peripheral T-cell lymphomas: 2017". Am J Hematol. 92 (7): 706–715. doi:10.1002/ajh.24791. PMID 28516671.
- ↑ Brandt PH, Rahmat LT, Ali SS (2019). "A rare case of hepatosplenic gamma-delta T-cell lymphoma and secondary hemophagocytic lymphohistiocytosis". Clin Case Rep. 7 (1): 164–169. doi:10.1002/ccr3.1924. PMC 6333078. PMID 30656034.
- ↑ Choi Y, Jeon SY, Yoo WH (2018). "Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor-α Inhibitors for Ankylosing Spondylitis". J Clin Rheumatol. doi:10.1097/RHU.0000000000000805. PMID 29933321.
- ↑ Gowda L, Foss F (2019). "Hepatosplenic T-Cell Lymphomas". Cancer Treat Res. 176: 185–193. doi:10.1007/978-3-319-99716-2_9. PMID 30596219.
- ↑ Gaulard P, Bourquelot P, Kanavaros P, Haioun C, Le Couedic JP, Divine M; et al. (1990). "Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas". Am J Pathol. 137 (3): 617–28. PMC 1877506. PMID 1698028.
- ↑ Yabe M, Miranda RN, Medeiros LJ (2018). "Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors". Hum Pathol. 74: 5–16. doi:10.1016/j.humpath.2018.01.005. PMID 29337025.
- ↑ Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE; et al. (2009). "Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment". Ann Oncol. 20 (6): 1080–5. doi:10.1093/annonc/mdn751. PMC 4092251. PMID 19237479.
- ↑ Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y; et al. (2016). "Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases". Am J Surg Pathol. 40 (5): 676–88. doi:10.1097/PAS.0000000000000614. PMID 26872013.